Noninvasive prenatal testing can uncover pregnancies at risk of miscarriage, New Scientist reports.
The firm reported $3.5 million in revenue for the three months ended Dec. 31, 2016, and $12.9 million for the full year.
The firm reported 29 percent growth in its overall testing revenues, driven mainly by higher reproductive test volume and higher per-test revenue.
CombiMatrix said the move will increase access to the test in the state for women experiencing recurrent pregnancy loss.
The company's testing was successful in more than 90 percent of cases over almost four years, and detected a wide variety of abnormalities.
The company reported an 18 percent increase in the number of reproductive health tests completed during the quarter.
The company feels it could be an attractive target for mergers, but is also keeping an eye out for IP acquisition options of its own.
The company said its revenue increase was driven by gains in test volume, particularly in miscarriage analysis and preimplantation genetic screening for couples undergoing IVF.
The research project, led by Kathy Niakan of the Francis Crick Institute, will involve editing several genes thought to be important to embryo development.
The UK Human Fertilisation & Embryology Authority is to consider an application submitted by researchers seeking to perform gene editing on human embryos.
The ancestors of the Arizona bark scorpion and other scorpions and spiders underwent whole-genome duplication, KJZZ reports.
A cryptographic approach could help researchers keep genomic data private while researchers analyze it, Scientific American reports.
Andy Page, the former president of 23andMe, has joined a diabetes-management startup, according to CNBC.
In Cell this week: regulatory changes in pancreatic cancer, metabolic shifts in Alzheimer's disease, and more.